Annual FCF
-$64.50 M
+$6.22 M+8.80%
December 31, 2023
Summary
- As of February 7, 2025, TCRX annual free cash flow is -$64.50 million, with the most recent change of +$6.22 million (+8.80%) on December 31, 2023.
- During the last 3 years, TCRX annual FCF has fallen by -$57.24 million (-788.36%).
- TCRX annual FCF is now -788.36% below its all-time high of -$7.26 million, reached on December 31, 2020.
Performance
TCRX Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly FCF
-$29.29 M
-$2.20 M-8.13%
September 30, 2024
Summary
- As of February 7, 2025, TCRX quarterly free cash flow is -$29.29 million, with the most recent change of -$2.20 million (-8.13%) on September 30, 2024.
- Over the past year, TCRX quarterly FCF has dropped by -$35.89 million (-543.89%).
- TCRX quarterly FCF is now -296.27% below its all-time high of $14.92 million, reached on June 30, 2020.
Performance
TCRX Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM FCF
-$110.58 M
-$35.89 M-48.04%
September 30, 2024
Summary
- As of February 7, 2025, TCRX TTM free cash flow is -$110.58 million, with the most recent change of -$35.89 million (-48.04%) on September 30, 2024.
- Over the past year, TCRX TTM FCF has dropped by -$52.93 million (-91.80%).
- TCRX TTM FCF is now -1384.94% below its all-time high of $8.61 million, reached on June 30, 2020.
Performance
TCRX TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Free Cash Flow Formula
FCF = Cash From Operations − CAPEX
TCRX Free Cash Flow Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
---|---|---|---|
1 y1 year | +8.8% | -543.9% | -91.8% |
3 y3 years | -788.4% | -543.9% | -91.8% |
5 y5 years | -368.5% | -543.9% | -91.8% |
TCRX Free Cash Flow Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
---|---|---|---|---|---|---|---|
3 y | 3-year | -10.0% | +8.8% | -543.9% | +2.3% | -91.8% | at low |
5 y | 5-year | -788.4% | +8.8% | -296.3% | +2.3% | -1384.9% | at low |
alltime | all time | -788.4% | +8.8% | -296.3% | +2.3% | -1384.9% | at low |
TScan Therapeutics Free Cash Flow History
Date | Annual | Quarterly | TTM |
---|---|---|---|
Sep 2024 | - | -$29.29 M(+8.1%) | -$110.58 M(+48.0%) |
Jun 2024 | - | -$27.09 M(-9.6%) | -$74.70 M(+6.6%) |
Mar 2024 | - | -$29.97 M(+23.7%) | -$70.05 M(+8.6%) |
Dec 2023 | -$64.50 M(-8.8%) | -$24.23 M(-467.3%) | -$64.50 M(+11.9%) |
Sep 2023 | - | $6.60 M(-129.4%) | -$57.66 M(-29.4%) |
Jun 2023 | - | -$22.44 M(-8.1%) | -$81.68 M(+9.6%) |
Mar 2023 | - | -$24.43 M(+40.5%) | -$74.50 M(+5.3%) |
Dec 2022 | -$70.73 M | -$17.39 M(-0.2%) | -$70.73 M(+1.1%) |
Sep 2022 | - | -$17.43 M(+14.2%) | -$69.93 M(+4.4%) |
Jun 2022 | - | -$15.26 M(-26.1%) | -$67.00 M(+1.0%) |
Date | Annual | Quarterly | TTM |
---|---|---|---|
Mar 2022 | - | -$20.66 M(+24.5%) | -$66.36 M(+13.2%) |
Dec 2021 | -$58.62 M(+707.3%) | -$16.59 M(+14.5%) | -$58.62 M(+15.5%) |
Sep 2021 | - | -$14.49 M(-0.9%) | -$50.76 M(+17.0%) |
Jun 2021 | - | -$14.62 M(+13.2%) | -$43.40 M(+213.1%) |
Mar 2021 | - | -$12.92 M(+47.9%) | -$13.86 M(+90.9%) |
Dec 2020 | -$7.26 M(-47.3%) | - | - |
Dec 2020 | - | -$8.73 M(+22.5%) | -$7.26 M(-592.6%) |
Sep 2020 | - | -$7.13 M(-147.8%) | $1.47 M(-82.9%) |
Jun 2020 | - | $14.92 M(-336.3%) | $8.61 M(-236.3%) |
Mar 2020 | - | -$6.32 M | -$6.32 M |
Dec 2019 | -$13.77 M | - | - |
FAQ
- What is TScan Therapeutics annual free cash flow?
- What is the all time high annual FCF for TScan Therapeutics?
- What is TScan Therapeutics annual FCF year-on-year change?
- What is TScan Therapeutics quarterly free cash flow?
- What is the all time high quarterly FCF for TScan Therapeutics?
- What is TScan Therapeutics quarterly FCF year-on-year change?
- What is TScan Therapeutics TTM free cash flow?
- What is the all time high TTM FCF for TScan Therapeutics?
- What is TScan Therapeutics TTM FCF year-on-year change?
What is TScan Therapeutics annual free cash flow?
The current annual FCF of TCRX is -$64.50 M
What is the all time high annual FCF for TScan Therapeutics?
TScan Therapeutics all-time high annual free cash flow is -$7.26 M
What is TScan Therapeutics annual FCF year-on-year change?
Over the past year, TCRX annual free cash flow has changed by +$6.22 M (+8.80%)
What is TScan Therapeutics quarterly free cash flow?
The current quarterly FCF of TCRX is -$29.29 M
What is the all time high quarterly FCF for TScan Therapeutics?
TScan Therapeutics all-time high quarterly free cash flow is $14.92 M
What is TScan Therapeutics quarterly FCF year-on-year change?
Over the past year, TCRX quarterly free cash flow has changed by -$35.89 M (-543.89%)
What is TScan Therapeutics TTM free cash flow?
The current TTM FCF of TCRX is -$110.58 M
What is the all time high TTM FCF for TScan Therapeutics?
TScan Therapeutics all-time high TTM free cash flow is $8.61 M
What is TScan Therapeutics TTM FCF year-on-year change?
Over the past year, TCRX TTM free cash flow has changed by -$52.93 M (-91.80%)